Skip to main content
. 2013 Nov 22;105(1):126–133. doi: 10.1111/cas.12305

Figure 2.

Figure 2

Cancer-specific survival in 101 patients with differentiated-type carcinoma based on phenotypic marker expression: (a) MUC5AC, (b) MUC6, (c) MUC2, and (d) CD10. For each marker, there was no significant difference between survival rates of patients whose tumors were positive or negative for the marker (MUC5AC, P = 0.303; MUC6, P = 0.307; MUC2, P = 0.387; and CD10, P = 0.470).